SPANXC Antibody

Basic Research Questions

• What is SPANXC and why is it significant in research?

SPANXC is a member of the SPANX (Sperm Protein Associated with the Nucleus on the X chromosome) family, which represents cancer/testis-specific antigens. The significance of SPANXC in research stems from its restricted expression pattern—primarily in testis under normal conditions but aberrantly expressed in various cancer types, particularly melanoma and carcinomas of lung, ovary, colon, and breast . This specific expression pattern makes SPANXC a potential target for cancer immunotherapy and a valuable biomarker for advanced disease stages, particularly in melanoma where its expression correlates with metastatic progression .

• What are the standard applications for SPANXC antibodies in research?

SPANXC antibodies are validated for multiple research applications:

When performing these applications, researchers should include appropriate positive controls (testis tissue or melanoma cells positive for SPANX proteins) and negative controls to validate specificity .

• What is the molecular weight of SPANXC protein detected by antibodies?

SPANXC appears as a band between 15-20 kDa on Western blots, with most studies reporting an observed molecular weight of approximately 17 kDa . The calculated molecular weight based on amino acid sequence is 11 kDa (97 amino acids) , but the apparent molecular weight in SDS-PAGE is higher, typically around 20 kDa . This discrepancy between theoretical and observed molecular weight is likely due to post-translational modifications or the protein's specific biochemical properties affecting migration in gels .

• How specific are commercially available SPANXC antibodies?

The specificity of SPANXC antibodies varies by manufacturer and clone. Due to high sequence homology within the SPANX family (particularly between SPANXA and SPANXC, which differ by only seven nucleotides ), cross-reactivity is a significant concern. Most commercially available antibodies recognize multiple SPANX family members .

According to published validation data, antibodies raised against specific peptide immunogens (amino acids 31-47 of human SPANXC ) show better specificity than those raised against full-length recombinant protein . Western blot validation using recombinant SPANX-B, SPANX-C, and SPANX-N proteins has shown that some antibodies react with multiple family members .

Advanced Research Questions

• How can I optimize Western blot protocols for detecting SPANXC in tumor samples?

Optimizing Western blot detection of SPANXC in tumor samples requires attention to several methodological details:

Protocol optimization:

• Sample preparation: Nuclear extraction is recommended as SPANXC is associated with nuclear structures

• Protein loading: Use 30 μg total protein per lane

• Gel conditions: 14% polyacrylamide gels under reducing conditions provide optimal resolution

• Transfer: Standard nitrocellulose membranes are suitable

• Blocking: 5% non-fat milk or commercial blocking solutions

• Primary antibody: 1:1000 dilution is most commonly reported for optimal signal-to-noise ratio

• Detection system: ECL Plus provides sufficient sensitivity for endogenous detection

Critical controls:

• Positive control: VWM105 melanoma cell line (SPANX-positive)

• Negative control: SPANX-negative cell lines or tissues

• Recombinant protein controls to confirm specificity

For tumors with potentially low expression, enhanced chemiluminescence detection systems or IRDye-conjugated secondary antibodies can improve sensitivity .

• What are the key differences in immunolocalization of SPANXC between normal testis and cancer tissues?

Immunolocalization studies reveal distinct patterns between testicular tissues and cancer samples:

In normal testis:

• SPANXC localizes to spermatozoa craters and cytoplasmic droplets in ejaculated spermatozoa

• These craters correspond to indentations on the nuclear surface and to vacuoles within condensed chromatin

• Expression is postmeiotic, representing one of the few examples of haploid expression from X-linked genes

In cancer tissues:

• SPANXC exhibits variable localization patterns in melanoma cells and tissues, being detected in:

  • Nuclear envelope (similar to localization in spermatids)

  • Cytoplasm

  • Both nuclear and cytoplasmic compartments simultaneously

• Advanced and metastatic melanomas show higher incidence of SPANXC-positive immunostaining

• Ultrastructural studies indicate association with the nuclear envelope in melanoma cells, resembling localization in human spermatids

This differential localization may reflect functional roles in nuclear organization or regulation in both germ cells and cancer cells .

• How can I distinguish between SPANXC and other SPANX family members in my experiments?

Distinguishing between highly homologous SPANX family members requires specific methodological approaches:

For RNA detection:

• Design custom TaqMan probes targeting the seven nucleotide differences between SPANXA and SPANXC

• Validate probe specificity using expression plasmids for each SPANX family member

• Use quantitative real-time PCR with these specific probes to distinguish expression levels

For example, researchers have designed the following probes to distinguish SPANXC from SPANXA:

• SPANXC forward primer: 5′-CGGGTCTGAGTCCCCAGTT-3′

• SPANXC reverse primer: 5′-TCCCCTGTGATTCCAACGA-3′

• SPANXC reporter sequence: 5′-CGGCATCGTCTCATTCAC-3′

For protein detection:

• Use immunoprecipitation followed by mass spectrometry to confirm antibody specificity

• Include recombinant SPANX family members as controls in Western blots

• Employ peptide competition assays using unique peptide sequences from each family member

• Consider regional expression patterns—SPANXC expression is much lower than SPANXA in some cell lines (e.g., CL1-0 and CL1-5)

Despite these approaches, complete distinction remains challenging due to high sequence homology.

• What is the genomic organization of SPANXC and how does this impact antibody design?

The genomic organization of SPANXC has important implications for antibody design and specificity:

Genomic arrangement:

• The SPANX gene family consists of five genes located in a cluster at Xq27.1

• From centromere to telomere, the arrangement is SPANXB, SPANXC, SPANXA1, SPANXA2, and SPANXD

• SPANXC is located approximately 238 kb away from SPANXB

• The SPANX genes evolved extremely rapidly, apparently under positive selection

Impact on antibody design:

• High sequence similarity between family members necessitates careful epitope selection

• Regions with higher sequence divergence (e.g., amino acids 31-47 of SPANXC) provide better targets for specific antibodies

• Polymorphisms in the SPANXC gene among individuals may impact antibody recognition—sequencing has revealed at least 41 SNPs in a 1112-bp segment of SPANXC

• Evidence of homology-based sequence transfer events between SPANX gene family members further complicates specific antibody development

Researchers should target unique epitopes while accounting for potential polymorphic variants in the human population when designing new antibodies against SPANXC.

• How reliable are SPANXC antibodies for clinical biomarker studies?

The reliability of SPANXC antibodies for clinical biomarker studies depends on several factors:

Strengths:

• SPANXC expression correlates with advanced and metastatic disease in melanoma, suggesting biomarker potential

• Multiple validated antibodies are available with established protocols for tissue microarray analysis

• Expression in multiple cancer types (melanoma, lung, ovarian, breast, and colon carcinomas) allows for broad application

Limitations:

• Approximately 50% of commercial antibodies fail to meet basic standards for characterization, impacting reproducibility

• Batch-to-batch variation, particularly in polyclonal antibodies, may affect consistency in longitudinal studies

• Cross-reactivity with other SPANX family members complicates interpretation of results

• Lack of standardized scoring systems for SPANXC expression in clinical samples

Recommendations for clinical biomarker studies:

• Validate antibody specificity with appropriate controls before clinical application

• Use multiple detection methods (IHC, qRT-PCR) for confirmation

• Include proper tissue controls (normal testis as positive control)

• Consider using antibodies that have been validated in tissue microarray studies

• Correlate SPANXC expression with established clinical parameters and outcomes

Researchers using SPANXC as a biomarker should acknowledge these limitations and implement strict validation protocols to ensure reliability.

• What are the T-cell epitopes of SPANXC relevant for immunotherapy research?

Research on SPANXC and its family member SPANX-B has identified several T-cell epitopes relevant for cancer immunotherapy:

CD4+ T-cell epitopes:

• Immunodominant HLA-DR-restricted epitope in SPANX-B: Pep-9 (amino acids 12-23)

• CD4+ T cells recognized DCs pulsed with SPANX-B peptides SPANX 11-31 (Pep-G1) and SPANX 12-35 (Pep-5)

• These epitopes are likely in the MHC class II immunodominant region between residues 11 and 35

CD8+ T-cell epitopes:

• Two HLA-A2-restricted epitopes in SPANX-B:

  • Pep-2 (amino acids 23-31)

  • Pep-4 (amino acids 57-65)

• These epitopes generated SPANX-B-specific CD8+ T cells from normal human PBLs that could recognize and kill HLA-matched human primary melanomas

Immunotherapeutic relevance:

• SPANXC/SPANX-B functions as an immunogenic antigen recognized by the human T-cell immune arm

• Healthy humans contain circulating SPANXC/SPANX-B-specific T-cell precursors that can be expanded

• Generated T cells include both helper CD4+ T cells and cytolytic CD8+ T cells

• SPANXC/SPANX-B-specific CD8+ T cells can recognize and efficiently kill HLA-matched human primary melanomas

These epitopes provide valuable targets for the development of protective and therapeutic cancer vaccines targeting SPANXC-expressing tumors.

• How do I optimize immunohistochemistry protocols for SPANXC detection in FFPE tissues?

Optimizing immunohistochemistry (IHC) for SPANXC detection in formalin-fixed, paraffin-embedded (FFPE) tissues requires specific methodological considerations:

Detailed IHC protocol optimization:

• Deparaffinization and rehydration:

  • Treat slides with xylene (three times for 5 min)

  • Series of ethanol washes (100%, 90%, 80%, 75%) for 2 minutes each

  • Rinse with PBS and water

• Antigen retrieval (critical step):

  • Use citrate buffer in a steamer for 25 minutes

  • This step is essential due to protein cross-linking during fixation

• Blocking:

  • Block with V-block solution (LabVision Corp) for 5 minutes

  • Follow with comprehensive blocking buffer (0.2% Triton X-100, 0.2% casein, 0.2% BSA, 5% normal goat serum, 0.2% gelatin, and 0.02% NaN3)

• Primary antibody:

  • Apply at a concentration of 5 μg/ml for FFPE tissues

  • Incubate at 4°C overnight for optimal results

• Detection system:

  • Use a sensitive detection system (e.g., polymer-based or avidin-biotin systems)

  • DAB (3,3'-diaminobenzidine) is commonly used as chromogen

• Counterstaining:

  • Light hematoxylin counterstain for nuclear visualization

Validation controls:

• Positive control: Human testis tissue (shows specific staining pattern)

• Negative control: Primary antibody omission

• Tissue microarrays can provide efficient multi-tumor analysis

Following this optimized protocol will help researchers achieve specific staining of SPANXC in FFPE tissues while minimizing background and false positives.

• What is the functional role of SPANXC in cancer progression and how can antibodies help elucidate this?

While the exact function of SPANXC in cancer remains under investigation, research with antibodies has provided several insights:

Current knowledge about SPANXC function:

• In contrast to SPANXA, which suppresses epithelial-mesenchymal transition (EMT) by inhibiting c-JUN/SNAI2 signaling in lung cancer , SPANXC's role is less defined

• SPANXC expression has been associated with advanced and metastatic disease in melanoma

• SPANXC's nuclear envelope localization in cancer cells resembles that in spermatids, suggesting potential roles in nuclear organization

• The protein may be involved in cancer stem-like cells and malignant progression

Antibody-based approaches to study function:

• Immunolocalization studies:

  • Track changes in SPANXC subcellular localization during cancer progression

  • Correlate localization patterns with clinical outcomes

• Protein interaction studies:

  • Co-immunoprecipitation with SPANXC antibodies to identify binding partners

  • Proximity ligation assays to confirm protein-protein interactions in situ

• Phenotypic studies:

  • Use antibodies to identify SPANXC-positive cells in heterogeneous tumor populations

  • Correlate expression with markers of stemness, invasion, or therapy resistance

• Functional blocking:

  • Investigate whether antibodies against extracellular or membrane-associated SPANXC can block function

  • Assess effects on cancer cell behavior (migration, invasion, survival)

• Expression correlation:

  • Combine SPANXC antibody staining with markers of EMT, proliferation, and cell death

  • Create comprehensive expression profiles of SPANXC-positive tumors

These approaches can help determine whether SPANXC is merely a biomarker or actively contributes to cancer progression, potentially identifying new therapeutic strategies.